Difference between revisions of "Coronavirus studies"
(added on to "see also" on the top of the page) |
(remove extraneous period, template) |
||
| Line 1: | Line 1: | ||
| − | <center>''See also: [[Flawed coronavirus studies]], [[Hydroxychloroquine denial]]'' | + | <center>''See also: [[Flawed coronavirus studies]], [[Hydroxychloroquine denial]]''</center> |
Numerous '''coronavirus studies''' demonstrate the prophylactic and early use of [[hydroxychloroquine]] against [[COVID-19]], which are being ignored or downplayed for political reasons. | Numerous '''coronavirus studies''' demonstrate the prophylactic and early use of [[hydroxychloroquine]] against [[COVID-19]], which are being ignored or downplayed for political reasons. | ||
| Line 20: | Line 20: | ||
In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with [[HCQ]]-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."<ref>https://www.sciencedirect.com/science/article/pii/S1477893920302817</ref> | In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with [[HCQ]]-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."<ref>https://www.sciencedirect.com/science/article/pii/S1477893920302817</ref> | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
{{coronavirus}} | {{coronavirus}} | ||
| − | |||
| − | |||
| − | |||
Revision as of 20:26, July 8, 2020
Numerous coronavirus studies demonstrate the prophylactic and early use of hydroxychloroquine against COVID-19, which are being ignored or downplayed for political reasons.
Here is a sampling of the growing list of valid studies confirming the effectiveness of hydroxychloroquine against COVID-19:
Minnesota data mining study
The incidence rate and mortality from COVID-19 was found to be lower in patients on chronic hydroxychloroquine therapy, in a large Minnesota healthcare system.
Between April 1, 2019 and March 31, 2020, the database contained 1,271,014 unique patient encounters, including a total of 2945 COVID-19 tests, of which 125 (4.24%) were positive.
Among the tests performed, 124 (4.35%) were positive for COVID-19 while not having taken hydroxychloroquine, while 96 tests were performed in patients with existing hydroxychloroquine prescriptions and only one (1.04%) was positive.
Two COVID-19 patients not on hydroxychloroquine died, while no COVID-19 patients not on hydroxychloroquine died.
Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.[1]
French study
In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."[2]